BERLEX SUES FDA CLAIMING BIOGEN's AVONEX VIOLATES BETASERON ORPHAN EXCLUSIVITY; FILES FOR RESTRAINING ORDER INDICATING AVONEX APPROVAL IS IMMINENT
Executive Summary
FDA approval of Biogen's Avonex (beta interferon) "is imminent," Berlex declares in a complaint filed April 26 in D.C. federal court seeking to block approval of the potential competitor for the Berlex multiple sclerosis therapy Betaseron.